Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immunotherapy for HCC: Current Evidence and Future Directions
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: November 24, 2020 Expiration: November 23, 2021
Start Activity
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group
Lipika Goyal, MD
Amit G. Singal, MD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, comorbid liver diseases, and patient characteristics and preferences
  • Review recent therapeutic advances and FDA approvals for the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Evaluate clinical data on the use of novel systemic for patients with relapsed/refractory advanced HCC and integrate this information into clinical practice, taking into consideration the available clinical evidence, preexisting cirrhosis and other liver diseases, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC, while also managing comorbid liver diseases
  • Plan strategies and care plans for coordination of treatment of HCC to maximize benefit for local and systemic therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit G. Singal, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exact Sciences, Exelixis, Genentech/Roche, Glycotest, GRAIL, Merck, and Wako.
Lipika Goyal, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Lipika Goyal, MD, MPhil, has disclosed that she has received consulting fees from Agios, Alentis, AstraZeneca, Debiopharm, H3 Biomedicine, Incyte, QED Therapeutics, Sirtex, and Taiho.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hepatologists, nurses, pharmacists, and other healthcare providers who care for patients with HCC.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in their clinical use of optimal HCC immunotherapy options.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-138-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 24, 2020, through November 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Immune Checkpoint Inhibitors in Contemporary Management of Advanced HCC
  • CME
  • CE

Loading...
In this segment, experts review data surrounding the use of immune checkpoint inhibitors for advanced HCC, with a discussion of how these agents fit into current treatment paradigms.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: November 24, 2020 Expiration: November 23, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

From Clinical Care Options (CCO), download slides reviewing key CAR T-cell therapy considerations for managed care and specialty pharmacy professionals

person default Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: August 4, 2021

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v3.2021, from CCO

Released: July 22, 2021

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Video Chapters


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue